Evidence map›Paper›PMID 35659272›Full record

ArticleFluids and barriers of the CNS2022

Effects of fasudil on blood-brain barrier integrity.

Kei Sato, Shinsuke Nakagawa, Yoichi Morofuji, Yuki Matsunaga, Takashi Fujimoto, Daisuke Watanabe, Tsuyoshi Izumo, Masami Niwa, Fruzsina R Walter, Judit P Vigh and 3 more

Open access · goldAbstract read
In one paragraph

Article in Fluids and barriers of the CNS, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Science advances · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Augmentation of functional recovery viaJournal of orthopaedic translation · 2024
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Kei SatoDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Shinsuke NakagawaDepartment of Pharmaceutical Care and Health Sciences, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Yoichi MorofujiDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. morofujiyoichi@gmail.com.ORCID http://orcid.org/0000-0001-7135-2220
Yuki MatsunagaDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Takashi FujimotoDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Daisuke WatanabeBBB Laboratory, PharmaCo-Cell Company Ltd, Nagasaki, 852-8135, Japan.
Tsuyoshi IzumoDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Masami NiwaBBB Laboratory, PharmaCo-Cell Company Ltd, Nagasaki, 852-8135, Japan.
Fruzsina R WalterBiological Barriers Research Group, Institute of Biophysics, Biological Research Centre, Szeged, 6726, Hungary.
Judit P VighBiological Barriers Research Group, Institute of Biophysics, Biological Research Centre, Szeged, 6726, Hungary.
Ana Raquel Santa-MariaBiological Barriers Research Group, Institute of Biophysics, Biological Research Centre, Szeged, 6726, Hungary.
Maria A DeliBiological Barriers Research Group, Institute of Biophysics, Biological Research Centre, Szeged, 6726, Hungary.
Takayuki MatsuoDepartment of Neurosurgery, Graduate School of Biomedical Sciences, Nagasaki University, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan.
Nagasaki University · JPHUN-REN Szegedi Biológiai Kutatóközpont · HUFukuoka University · JPHarvard University · US

Funding

Japan Society for the Promotion of Science 20K09351Japan Society for the Promotion of Science 20KK0254Japan Society for the Promotion of Science 211032Japan Society for the Promotion of Science JPJSBP120203804
6 · The paper itself

Abstract

backgroundCerebral infarction accounts for 85% of all stroke cases. Even in an era of rapid and effective recanalization using an intravascular approach, the majority of patients have poor functional outcomes. Thus, there is an urgent need for the development of therapeutic agents to treat acute ischemic stroke. We evaluated the effect of fasudil, a Rho kinase inhibitor, on blood brain barrier (BBB) functions under normoxia or oxygen-glucose deprivation (OGD) conditions using a primary cell-based in vitro BBB model.

methodsBBB models from rat primary cultures (brain capillary endothelial cells, astrocytes, and pericytes) were subjected to either normoxia or 6 h OGD/24 h reoxygenation. To assess the effects of fasudil on BBB functions, we evaluated real time impedance, transendothelial electrical resistance (TEER), sodium fluorescein permeability, and tight junction protein expression using western blotting. Lastly, to understand the observed protective mechanism on BBB functions by fasudil we examined the role of cyclooxygenase-2 and thromboxane A2 receptor agonist U-46619 in BBB-forming cells.

resultsWe found that treatment with 0.3-30 µM of fasudil increased cellular impedance. Fasudil enhanced barrier properties in a concentration-dependent manner, as measured by an increased (TEER) and decreased permeability. Fasudil also increased the expression of tight junction protein claudin-5. Reductions in TEER and increased permeability were observed after OGD/reoxygenation exposure in mono- and co-culture models. The improvement in BBB integrity by fasudil was confirmed in both of the models, but was significantly higher in the co-culture than in the monoculture model. Treatment with U-46619 did not show significant changes in TEER in the monoculture model, whereas it showed a significant reduction in TEER in the co-culture model. Fasudil significantly improved the U-46619-induced TEER reduction in the co-culture models. Pericytes and astrocytes have opposite effects on endothelial cells and may contribute to endothelial injury in hyperacute ischemic stroke. Overall, fasudil protects the integrity of BBB both by a direct protective effect on endothelial cells and by a pathway mediated via pericytes and astrocytes.

conclusionsOur findings suggest that fasudil is a BBB-protective agent against acute ischemic stroke.

Indexed as

Blood-Brain BarrierIschemic Stroke15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAnimalsAstrocytesEndothelial CellsGlucoseHumansRatsTight Junction Proteins15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid1-(5-Isoquinolinesulfonyl)-2-MethylpiperazinefasudilGlucoseTight Junction ProteinsAcute ischemic strokeAstrocytesBlood–brain barrierFasudilOxygen–glucose deprivation-reoxygenationPericytesRho-kinase inhibitorThromboxane A2Tight junction

Identifiers

PMID35659272
PMCPMC9166508
OpenAlexW4281821949

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.